VA-REGULA
14.5.2024 09:01:37 CEST | Business Wire | Press release
MWC attracts tens of thousands of visitors, including representatives of mobile operators, device manufacturers, technology providers, vendors, and content owners. To ensure everyone's safety, the GSMA has traditionally conducted thorough registration and ID validation processes for each attendee.
For many years, the ID validation process was done on-site at the venue, which caused queues and long wait times. With the advent of the pandemic in 2020, and attendance now regularly exceeding 100,000, the GSMA had to find a contactless solution to remove the need to have attendees wait in large numbers to collect badges and have their ID validated. To address these issues and improve the efficiency of the registration process, the GSMA decided to make it totally remote and digital, so that all attendees could swiftly get access to the venue through the entry gates. Any solution would also need to enable quick and efficient international document recognition, because attendees come from all over the world.
To achieve their goal, the GSMA ran an extensive competitive tender process to find the best technology solution. Ultimately, they chose a complete, single-vendor solution by Regula which includes Regula Document Reader SDK and Regula Face SDK. Natively integrated, these solutions facilitate a smooth customer journey and rapid onboarding through seamless and secure identity verification, eliminating the possibility of fraud.
Having successfully piloted Regula products during MWC Barcelona 2021, the GSMA fully transitioned to digital visitor registration and ID validation. After several years of collaboration, this long-term partnership led to a significant enhancement of the visitor registration process, enabling a fast and convenient user experience. Now, Regula Document Reader SDK and Regula Face SDK are easily integrated into the MWC’s existing registration platform for full-fledged production use.
Now, as part of the registration process, an MWC visitor simply uploads their ID on the official website. The identity document is automatically scanned by Regula Document Reader SDK. The solution instantly recognizes the document type, reads its data, and verifies its authenticity with multiple cross-checks. Not only does it streamline the verification process (checks are completed in seconds), but it also minimizes the chance of missing compromised IDs.
Further, an MWC attendee has the opportunity to provide their selfie, which is rapidly captured by Regula Face SDK for user verification.
With the industry’s largest and most comprehensive identity document template database, which contains over 13,600 templates from 249 countries and territories, Regula supports the verification of nearly any identity document from any part of the world. Taking into account MWC attendees’ geographical spread, this ability significantly facilitates the registration process.
With Regula’s complete IDV solution, the GSMA managed to create a custom, smooth, and seamless registration experience for all MWC attendees. During the Barcelona event in 2024, Regula solutions helped to efficiently validate more than 100,000 visitors – all of them registered online beforehand, so there was no need to queue at the venue.
"Our collaboration with GSMA for MWC highlights the power of digital transformation in handling large-scale international events. By integrating our advanced ID verification technologies, not only did we enhance the security and efficiency of the registration process, but also ensured a seamless experience for attendees," says Ihar Kliashchou, Chief Technology Officer at Regula.
“The digital identity verification process has revolutionized the visitor experience, allowing more than 100,000 individuals to register and access the world’s leading connectivity event swiftly, safely, and without interruption," states Xavi Casals, Director of Technology, Innovation & Customer Experience at GSMA.
For more details on the business case, please visit the Regula website.
About GSMA
The GSMA is a global organisation unifying the mobile ecosystem to discover, develop and deliver innovation foundational to positive business environments and societal change. Our vision is to unlock the full power of connectivity so that people, industry and society thrive. Representing mobile operators and organisations across the mobile ecosystem and adjacent industries, the GSMA delivers for its members across three broad pillars: Connectivity for Good, Industry Solutions and Events.
Find out more at gsma.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514134027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
